Capital Management Associates Stake in Broadridge Financial Solutions (BR) Has Decreased by $515,250; Abbott Labs (ABT) Shares Rose While Banque Pictet & Cie Sa Cut Its Holding by $1.71 Million

April 17, 2018 - By wolcottdaily

Abbott Laboratories (NYSE:ABT) Logo

Banque Pictet & Cie Sa decreased its stake in Abbott Labs (ABT) by 7.43% based on its latest 2017Q4 regulatory filing with the SEC. Banque Pictet & Cie Sa sold 29,996 shares as the company’s stock rose 5.88% while stock markets declined. The institutional investor held 373,738 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $21.33M, down from 403,734 at the end of the previous reported quarter. Banque Pictet & Cie Sa who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $103.86B market cap company. The stock increased 0.35% or $0.205 during the last trading session, reaching $59.475. About 2.03M shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since April 17, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Capital Management Associates decreased its stake in Broadridge Financial Solutions (BR) by 34.24% based on its latest 2017Q4 regulatory filing with the SEC. Capital Management Associates sold 5,725 shares as the company’s stock rose 18.02% while stock markets declined. The institutional investor held 10,996 shares of the miscellaneous company at the end of 2017Q4, valued at $996,000, down from 16,721 at the end of the previous reported quarter. Capital Management Associates who had been investing in Broadridge Financial Solutions for a number of months, seems to be less bullish one the $12.99B market cap company. The stock increased 1.49% or $1.63 during the last trading session, reaching $111.34. About 318,645 shares traded. Broadridge Financial Solutions, Inc. (NYSE:BR) has risen 58.90% since April 17, 2017 and is uptrending. It has outperformed by 47.35% the S&P500.

Banque Pictet & Cie Sa, which manages about $5.01 billion US Long portfolio, upped its stake in Procter And Gamble Co (NYSE:PG) by 369,236 shares to 1.55M shares, valued at $142.32 million in 2017Q4, according to the filing. It also increased its holding in Select Sector Spdr Tr (XLE) by 73,746 shares in the quarter, for a total of 1.30 million shares, and has risen its stake in Microsoft Corp (NASDAQ:MSFT).

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. BMO Capital Markets maintained it with “Hold” rating and $4800 target in Monday, July 10 report. As per Monday, April 17, the company rating was maintained by Cowen & Co. On Friday, January 29 the stock rating was downgraded by William Blair to “Market Perform”. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies on Wednesday, January 24. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Stifel Nicolaus on Thursday, July 23. Jefferies maintained it with “Buy” rating and $55 target in Friday, June 16 report. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies on Monday, December 7. On Tuesday, June 14 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by RBC Capital Markets on Friday, September 1 with “Buy”. The rating was maintained by Morgan Stanley on Thursday, October 19 with “Equal-Weight”.

Since October 23, 2017, it had 1 buy, and 19 insider sales for $28.95 million activity. $1.56M worth of stock was sold by Salvadori Daniel Gesua Sive on Thursday, December 14. $667,804 worth of stock was sold by Fussell Stephen R on Wednesday, February 28. On Wednesday, February 28 the insider Watkin Jared sold $58,635. Funck Robert E sold $71,970 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, February 28. Ford Robert B also sold $2.69M worth of Abbott Laboratories (NYSE:ABT) shares. $1.73M worth of stock was sold by Blaser Brian J on Wednesday, January 31.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on April, 18 before the open. They expect $0.58 EPS, up 20.83% or $0.10 from last year’s $0.48 per share. ABT’s profit will be $1.01 billion for 25.64 P/E if the $0.58 EPS becomes a reality. After $0.74 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts -21.62% negative EPS growth.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.04, from 0.87 in 2017Q3. It improved, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Hikari Tsushin Inc accumulated 0.49% or 32,870 shares. 1.34 million were reported by Korea Investment Corp. Phocas owns 0.02% invested in Abbott Laboratories (NYSE:ABT) for 4,360 shares. Seabridge Investment Advsrs Limited Liability Com owns 2,875 shares for 0.04% of their portfolio. Kemper Corp Master Retirement holds 1.62% of its portfolio in Abbott Laboratories (NYSE:ABT) for 49,900 shares. Mercer Cap Advisers invested 0.01% in Abbott Laboratories (NYSE:ABT). Macroview Mgmt Lc holds 0.09% in Abbott Laboratories (NYSE:ABT) or 324 shares. Stralem Co Inc stated it has 273,695 shares or 2.65% of all its holdings. Wolverine Asset Management Ltd Company reported 0% in Abbott Laboratories (NYSE:ABT). Gofen And Glossberg Ltd Company Il accumulated 463,675 shares or 0.95% of the stock. Ramsay Stattman Vela Price holds 3.09% or 136,569 shares in its portfolio. Aqr Cap Limited Liability Co reported 410,394 shares or 0.02% of all its holdings. Douglass Winthrop Ltd Liability Co stated it has 42,181 shares. Overbrook has 11,253 shares. Capital reported 0.13% of its portfolio in Abbott Laboratories (NYSE:ABT).

Investors sentiment increased to 1.14 in 2017 Q4. Its up 0.13, from 1.01 in 2017Q3. It improved, as 20 investors sold BR shares while 168 reduced holdings. 73 funds opened positions while 141 raised stakes. 95.28 million shares or 0.24% less from 95.51 million shares in 2017Q3 were reported. Mutual Of America Cap Mgmt Ltd has 0.13% invested in Broadridge Financial Solutions, Inc. (NYSE:BR). Glenmede Na owns 3,875 shares for 0% of their portfolio. Verition Fund Mngmt Ltd Limited Liability Company holds 0.03% or 3,821 shares. Welch And Forbes Ltd Company invested in 6,681 shares or 0.02% of the stock. The California-based Wetherby Asset Management Inc has invested 0.03% in Broadridge Financial Solutions, Inc. (NYSE:BR). Webster National Bank N A holds 0.01% or 825 shares in its portfolio. Pinebridge Invests LP holds 0.29% or 124,467 shares in its portfolio. Oakbrook Investments Limited Com reported 0.05% stake. Tiaa Cref Inv Ltd Company reported 505,132 shares. Commerzbank Aktiengesellschaft Fi, Germany-based fund reported 17,286 shares. Moreover, Bbva Compass Financial Bank has 0.02% invested in Broadridge Financial Solutions, Inc. (NYSE:BR). Northern Tru Corporation invested in 1.71M shares. Sterling Capital Mngmt Ltd Llc reported 2,244 shares. Wade G W And has invested 0.06% of its portfolio in Broadridge Financial Solutions, Inc. (NYSE:BR). Aull & Monroe Management holds 0.14% or 3,014 shares.

Among 7 analysts covering Broadridge Financial Solutions (NYSE:BR), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. Broadridge Financial Solutions had 19 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of Broadridge Financial Solutions, Inc. (NYSE:BR) earned “Market Perform” rating by Raymond James on Tuesday, June 7. The rating was initiated by Barclays Capital with “Overweight” on Wednesday, September 16. The stock has “Hold” rating by Sandler O’Neill on Thursday, February 8. The stock of Broadridge Financial Solutions, Inc. (NYSE:BR) has “Neutral” rating given on Wednesday, March 28 by DA Davidson. The stock of Broadridge Financial Solutions, Inc. (NYSE:BR) earned “Equal-Weight” rating by Barclays Capital on Wednesday, August 10. The firm has “Market Outperform” rating given on Friday, January 8 by Avondale. The rating was initiated by Atlantic Securities with “Overweight” on Tuesday, September 13. As per Wednesday, June 15, the company rating was downgraded by Avondale. The firm has “Hold” rating given on Thursday, February 15 by Sandler O’Neill. The firm has “Sell” rating by Zacks given on Friday, August 14.

Analysts await Broadridge Financial Solutions, Inc. (NYSE:BR) to report earnings on May, 9. They expect $0.79 EPS, up 14.49% or $0.10 from last year’s $0.69 per share. BR’s profit will be $92.15 million for 35.23 P/E if the $0.79 EPS becomes a reality. After $0.79 actual EPS reported by Broadridge Financial Solutions, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: